Hungarian pharmaceutical company Gedeon Richter Plc. and Dr. Max BDC, s.r.o. (‘Dr.Max Group’) have announced that Richter’s indirect Romanian subsidiary, Armedica Trading S.R.L has signed a share sale and purchase agreement to divest the Richter Group’s Romanian wholesale and retail operations (Pharmafarm S.A. and Gedeon Richter Farmacia S.A., respectively) to Mediplus Exim S.R.L (“Mediplus”), a Romanian subsidiary of A&D Pharma, both being members of Dr.Max Group.
The purchase price is due on the closure of the transaction pending on the approval of the Romanian competition authority.
“This agreement follows the divesture of similar non-core businesses in the Republic of Moldova last year and it further increases strategic focus on core activities. The sustained protection of high margins achieved by our highly specialised pharmaceutical business segment is of paramount importance to Richter management,” said Richter CEO, Gábor Orbán said.
“The acquisition of Richter Group’s pharmaceutical retail and wholesale operations in Romania marks another big step in the expansion of Dr.Max Group on the Romanian Market and further solidifies our position among the Europe’s leading pharmacy chains,” according to Dr. Max Group CEO, Leonardo Ferrandino,.
“Thanks to this transaction, we will strengthen our position on retail as well as wholesale market. Due to a very limited overlap with our retail chain, the contemplated acquisition will allow us to cover a few white spots within our grid and provide more convenient services and wide product portfolio to our patients at locations we are already present. Hence, the transaction perfectly fits into our strategy,” the CEO of A&D Pharma, Cezar Zaharia added.


Leave a Reply Cancel reply
Top 5 Articles
L'Oréal Appoints New Managing Director in the Region January 6, 2025
Chimborazo February 14, 2025
New President at the American Chamber of Commerce December 11, 2024
A Photographer's Passion for Polar Frontiers February 12, 2025
Hungary Slashes Guest Worker Quota for 2025 December 27, 2024
No comment yet. Be the first!